<DOC>
	<DOCNO>NCT00003605</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy monoclonal antibody therapy may kill cancer cell . PURPOSE : Phase II trial study effectiveness rituximab plus cyclophosphamide treating patient indolent stage III stage IV non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Rituximab Plus Cyclophosphamide Treating Patients With Indolent Stage III Stage IV Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity associate cyclophosphamide rituximab ( IDEC-C2B8 monoclonal antibody ) first line treatment patient stage III IV indolent B-cell lymphoma . II . Determine objective tumor response rate duration response associate first line treatment patient . III . Determine failure-free overall survival patient . IV . Compare response rate survival rate patient indolent lymphoma treat treatment first systemic therapy disease response rate survival observed similar patient treat publish trial . V. Determine quality life associate treatment patient population . OUTLINE : This open label study . Patients receive oral cyclophosphamide daily rituximab ( IDEC-C2B8 monoclonal antibody ) IV day 1 , 8 , 15 , 22 first 4-week course . Patients receive oral cyclophosphamide daily rituximab IV monthly 2 month beyond maximum response . Patients treat least 6 month 18 month absence disease progression . Patients follow every 3 month 2 year , every 6 month next 2 year , annually 10 year . PROJECTED ACCRUAL : There 20-40 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage III IV indolent Bcell lymphoma Diffuse small cleave cell lymphoma Follicular small cleave cell lymphoma Follicular mix cell lymphoma Follicular large cell lymphoma At least 1 lymph node visceral lesion least 2 cm diameter PATIENT CHARACTERISTICS : Age : Not specify Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Lymphocyte count le 5,000/mm3 Hepatic : Not specify Renal : Not specify Other : No active infection No concurrent life threaten disease Not pregnant Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : No prior therapy lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>